Skin bioMARkers for Atopic Eczema Therapy Evaluation
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate two new non-invasive technologies for assessing skin properties
to identify and validate a range of safety biomarkers that may be considered useful as
primary outcome measures for evaluating the safety of topical treatments in atopic
dermatitis. The method of assessing these biomarker technologies will be to determine whether
twice daily treatment with crisaborole (2%) ointment, compared to betamethasone valerate
(0.1%) cream, for up to 4 weeks, may cause skin structure or function changes, like skin
atrophy, in patients with atopic dermatitis (AD).